| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
AUSTIN, Texas & NORTHBROOK, Ill.—Luminex Corp. and Nanosphere Inc. announced May 16 that they had entered into a definitive agreement under which Luminex will acquire Nanosphere, a player in the molecular microbiology and molecular diagnostic market, for $1.35 per share in an all-cash transaction valued at approximately $58 million. 
 
Luminex calls Nanosphere an “ideal strategic fit” thanks its Verigene platform, broad menu and strong presence in the molecular microbiology market—that last item reportedly providing more than 240 customers that complement Luminex’s customer base.
 
In addition, bringing Nanosphere into Luminex’s fold is expected to amplify Luminex’s market leadership, given that, as the company reports, “Nanosphere’s Verigene technology leads in the high-growth bloodstream infection segment and complements Luminex’s current infectious disease portfolio. Following the acquisition, only Luminex will be able to offer customers automated molecular platforms for both syndromic and targeted molecular diagnostic testing (Verigene and ARIES).”
 
Finally, the deal is said to offer attractive economics and shareholder value, as Nanosphere’s forecasted 2016 revenue of between $28 million and $30 million “will immediately accelerate Luminex’s stand-alone projected revenue growth, reflecting Nanosphere’s high double-digit revenue growth and the ability to leverage Luminex’s global molecular diagnostic distribution. Nanosphere’s total revenue for 2015 was $21 million.”
 
In commenting on the acquisition deal, Zacks Investment Research pointed out the recently announced impressive first-quarter results for Luminex—among them the fact that earnings grew 36.5 percent on a year-over-year basis and assay revenues increased 6.3 percent to $27 million (reportedly reflecting the successful execution of the company’s molecular diagnostic strategy).
 
Infectious disease assay sales made up about 72 percent of the total assay sales in the quarter and genetic testing assays made up the rest. Meanwhile, the molecular diagnostic business brought in some $28 million in revenues, which was driven by a 20-percent growth in Luminex’s infectious disease test portfolio.
 
“In this regard, the addition of Nanosphere will contribute revenues in the range of $13-$16 million to this business line, if the deal completes by July 1,” Zacks wrote. “Luminex noted that the transaction will be accretive to its adjusted earnings by the end of full-year 2017.”
 
“The acquisition of Nanosphere will significantly enhance Luminex’s growth trajectory by expanding our product portfolio, delivering access to new markets and strengthening our pipeline of future products to make us the partner of choice for all molecular labs,” said Homi Shamir, president and CEO of Luminex.  “The deal demonstrates prudent execution of our fourth strategic growth pillar: leveraging our financial strength to accelerate growth in our target markets.”
 
“Luminex will recognize significant strategic benefit moving forward as our customer base and leverage in our expanding menu contribute to accelerated revenue growth,” said Michael McGarrity, president and CEO of Nanosphere. “The resources and reputation for excellence that Luminex carries in the market will greatly benefit our customers and employees.”
 
TheStreet.com reported the day of the announcement that “So far today, 11.15 million shares of Nanosphere have exchanged hands, significantly higher than its average daily volume of 86,183 shares … Separately, Nanosphere has a ‘sell’ rating and a letter grade of D- at TheStreet Ratings because of the compan’s disappointing return on equity and generally disappointing stock performance.”

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

GreenCooling

Thermo Scientific™ Centrifuges with GreenCool Technology

Next-generation natural refrigerant cooling system for centrifuges, offering a lower Global Warming Potential and reduced energy consumption.
Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue